- Home
- ELVN vs SAFT Comparison
ELVN vs SAFT Comparison
Compare ELVN & SAFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELVN
- SAFT
- Stock Information
- Founded
- ELVN 2016
- SAFT 1979
- Country
- ELVN United States
- SAFT United States
- Employees
- ELVN N/A
- SAFT N/A
- Industry
- ELVN Biotechnology: Pharmaceutical Preparations
- SAFT Property-Casualty Insurers
- Sector
- ELVN Health Care
- SAFT Finance
- Exchange
- ELVN Nasdaq
- SAFT Nasdaq
- Market Cap
- ELVN 1.1B
- SAFT 1.2B
- IPO Year
- ELVN 2020
- SAFT N/A
- Fundamental
- Price
- ELVN $27.53
- SAFT $81.73
- Analyst Decision
- ELVN Strong Buy
- SAFT
- Analyst Count
- ELVN 3
- SAFT 0
- Target Price
- ELVN $34.33
- SAFT N/A
- AVG Volume (30 Days)
- ELVN 309.7K
- SAFT 44.2K
- Earning Date
- ELVN 11-07-2024
- SAFT 10-30-2024
- Dividend Yield
- ELVN N/A
- SAFT 4.41%
- EPS Growth
- ELVN N/A
- SAFT 43.98
- EPS
- ELVN N/A
- SAFT 3.45
- Revenue
- ELVN N/A
- SAFT $1,025,770,000.00
- Revenue This Year
- ELVN N/A
- SAFT N/A
- Revenue Next Year
- ELVN N/A
- SAFT N/A
- P/E Ratio
- ELVN N/A
- SAFT $23.24
- Revenue Growth
- ELVN N/A
- SAFT 18.98
- 52 Week Low
- ELVN $9.80
- SAFT $68.98
- 52 Week High
- ELVN $27.67
- SAFT $89.46
- Technical
- Relative Strength Index (RSI)
- ELVN 73.14
- SAFT 47.43
- Support Level
- ELVN $24.60
- SAFT $80.10
- Resistance Level
- ELVN $27.55
- SAFT $83.26
- Average True Range (ATR)
- ELVN 1.41
- SAFT 1.35
- MACD
- ELVN 0.40
- SAFT -0.12
- Stochastic Oscillator
- ELVN 98.56
- SAFT 41.27
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations.
About SAFT Safety Insurance Group Inc.
Safety Insurance Group Inc is a provider of private passenger automobile insurance in Massachusetts. The company also offers property and casualty insurance products, including commercial automobiles, homeowners, dwelling fire, umbrella, and business owner policies. It operates in the business segment of Property and casualty insurance operations.